Two Versus One Week Breast Radiotherapy (RT)
Sponsor: Weill Medical College of Cornell University
ClinicalTrials ID:NCT06960707
This study compares two radiotherapy regimens for early breast cancer: a 1-week course of 2600 cGy in 5 fractions and a 2-week course of 3200 cGy with a 3600 cGy boost in 10 fractions. Eligible participants are women post-segmental mastectomy with specific cancer criteria. The trial evaluates side effects, breast appearance, and cancer control, aiming to determine long-term efficacy.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.
Description
Radiotherapy: one week (Arm 1) 2600 cGy in 5 fractions whole breast radiotherapy over one week versus 2 weeks (Arm 2), 3200 cGy in 10 fractions with a concomitant tumor bed boost to 3600 cGy. In Arm 2, if no cavity is visible due to oncoplastic surgery, we will deliver 32 Gy to the whole breast only, without a boost.
Hypothesis: A regimen of whole breast radiotherapy to 2600 in five fractions, the current UK standard for early breast cancer (Arm 2), is not inferior to 3200cGy with a concomitant tumor bed boost to 3600 cGy in 10 fractions (Arm 1), in terms of acute toxicity and long-term fibrosis, breast cosmesis and local control at 2 and 5 years. It will also test the hypothesis of superior local control at 10 years in Arm 2 compared to Arm 1.
Eligibility Criteria
Inclusion Criteria
- Women status post segmental mastectomy.
- If unilateral, pT1-2 breast cancer excised with negative margins.
- If bilateral, pT1-2 breast cancer excised with negative margins AND/OR pTis excised with negative margins.
- Clinically N0 (cN0 as determined by ultrasound/SOUND criteria) or pN0-1 or Nx or sentinel node negative.
- Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).
- Women with previous contralateral treated breast cancer can be enrolled in the trial.
Exclusion Criteria
- Previous radiation therapy to the ipsilateral breast.
- >90 days from last surgery, unless s/p adjuvant chemotherapy.
- >60 days from last chemotherapy.
- Male breast cancer.
- Ongoing treatment for severe autoimmune disease.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Brooklyn Methodist Hospital | 11215 | New York | New York |
| New York Presbyterian Hospital | 11355 | New York | New York |
| New York-Presbyterian Weill Cornell Medical College | 11355 | New York | New York |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.